TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
TriSalus Life Sciences (Nasdaq: TLSI), an oncology company focused on improving outcomes for liver and pancreatic cancer patients, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. Mary Szela, CEO and President of TriSalus, will engage in a fireside chat on Thursday, October 17, 2024, at 12:30 p.m. EDT / 11:30 a.m. CDT.
TriSalus specializes in advanced delivery technology and a novel immunotherapy called nelitolimod. The company aims to enhance treatment outcomes for patients with liver and pancreatic cancer. Interested parties can register for the event through the provided link and find more information about TriSalus and its innovative technologies on the company's website.
TriSalus Life Sciences (Nasdaq: TLSI), un'azienda oncologica concentrata sul miglioramento dei risultati per i pazienti con cancro al fegato e al pancreas, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Mary Szela, CEO e Presidente di TriSalus, parteciperà a una conversazione informale giovedì 17 ottobre 2024, alle 12:30 EDT / 11:30 CDT.
TriSalus è specializzata in tecnologie avanzate di somministrazione e in una nuova immunoterapia chiamata nelitolimod. L'azienda mira a migliorare i risultati terapeutici per i pazienti affetti da cancro al fegato e al pancreas. Le parti interessate possono registrarsi per l'evento attraverso il link fornito e trovare maggiori informazioni su TriSalus e le sue tecnologie innovative sul sito web dell'azienda.
TriSalus Life Sciences (Nasdaq: TLSI), una empresa de oncología centrada en mejorar los resultados para los pacientes con cáncer de hígado y de páncreas, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. Mary Szela, CEO y Presidenta de TriSalus, participará en una charla informal el jueves 17 de octubre de 2024, a las 12:30 p.m. EDT / 11:30 a.m. CDT.
TriSalus se especializa en tecnología avanzada de entrega y en una nueva inmunoterapia llamada nelitolimod. La empresa tiene como objetivo mejorar los resultados del tratamiento para los pacientes con cáncer de hígado y de páncreas. Las partes interesadas pueden registrarse para el evento a través del enlace proporcionado y encontrar más información sobre TriSalus y sus tecnologías innovadoras en el sitio web de la empresa.
TriSalus Life Sciences (Nasdaq: TLSI)는 간과 췌장암 환자의 치료 결과 개선에 주력하는 종양학 회사로, 2024 Maxim Healthcare Virtual Summit에 참가한다고 발표했습니다. Mary Szela TriSalus의 CEO이자 사장은 2024년 10월 17일 목요일, 오후 12시 30분 EDT / 오전 11시 30분 CDT에 열린 담소에 참가할 예정입니다.
TriSalus는 고급 전달 기술과 nelitolimod라는 새로운 면역 요법에 전문화되어 있습니다. 이 회사는 간과 췌장암 환자의 치료 결과를 향상시키는 것을 목표로 하고 있습니다. 관심 있는 분들은 제공된 링크를 통해 이벤트에 등록할 수 있으며, 회사 웹사이트에서 TriSalus 및 그 혁신적인 기술에 대한 추가 정보를 찾을 수 있습니다.
TriSalus Life Sciences (Nasdaq: TLSI), une entreprise oncologique axée sur l'amélioration des résultats pour les patients atteints de cancer du foie et du pancréas, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Mary Szela, PDG et Présidente de TriSalus, participera à une discussion informelle jeudi 17 octobre 2024, à 12h30 EDT / 11h30 CDT.
TriSalus se spécialise dans les technologies de delivery avancées et une nouvelle immunothérapie appelée nelitolimod. L'entreprise vise à améliorer les résultats des traitements pour les patients souffrant de cancer du foie et du pancréas. Les parties intéressées peuvent s'inscrire à l'événement via le lien fourni et trouver plus d'informations sur TriSalus et ses technologies innovantes sur le site Web de l'entreprise.
TriSalus Life Sciences (Nasdaq: TLSI), ein onkologisches Unternehmen, das sich auf die Verbesserung der Ergebnisse für Patienten mit Leber- und Bauchspeicheldrüsenkrebs konzentriert, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit angekündigt. Mary Szela, CEO und Präsidentin von TriSalus, wird am Donnerstag, den 17. Oktober 2024, um 12:30 Uhr EDT / 11:30 Uhr CDT an einem informellen Gespräch teilnehmen.
TriSalus ist auf fortschrittliche Liefertechnologie und eine neuartige Immuntherapie namens nelitolimod spezialisiert. Das Unternehmen hat sich zum Ziel gesetzt, die Behandlungsergebnisse für Patienten mit Leber- und Bauchspeicheldrüsenkrebs zu verbessern. Interessierte können sich über den bereitgestellten Link für die Veranstaltung registrieren und weitere Informationen zu TriSalus und seinen innovativen Technologien auf der Website des Unternehmens finden.
- None.
- None.
Details for the fireside chat are as follows:
Date: Thursday, October 17, 2024
Time: 12:30 p.m. EDT / 11:30 a.m. CDT
Presenter: Mary Szela, Chief Executive Officer and President of TriSalus
To attend the event, please register by clicking here.
For more information about TriSalus Life Sciences and its innovative technologies, please visit www.trisaluslifesciences.com.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.
The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014472226/en/
For Media Inquiries:
Stephanie Jacobson
Argot Partners
610.420.3049
TriSalus@argotpartners.com
For Investor Inquiries:
James Young
SVP-Investor Relations/Treasurer
847.337.0655
james.young@trisaluslifesci.com
Source: TriSalus Life Sciences
FAQ
When is TriSalus Life Sciences (TLSI) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent TriSalus Life Sciences (TLSI) at the 2024 Maxim Healthcare Virtual Summit?
What is the focus of TriSalus Life Sciences (TLSI)?
How can interested parties attend the TriSalus Life Sciences (TLSI) presentation at the 2024 Maxim Healthcare Virtual Summit?
